Bryan Goodwin

Bryan Goodwin has extensive work experience in the pharmaceutical industry. Bryan is currently the Senior Vice President, Head of Biology and Translational Sciences at Morphic Therapeutic since March 2023. Prior to that, they worked at Enanta Pharmaceuticals from November 2017 to March 2023 as the Vice President, Head of Biology. Bryan also worked at Shire from March 2016 to October 2017 as the Senior Director, Head of Gastrointestinal, Metabolic, and Endocrine Research Therapeutic Area. At Pfizer, Bryan held various senior roles such as Senior Director, Muscle Metabolism, Cardiovascular and Metabolic Disease Research Unit from April 2014 to March 2016, Director, Diabetes Prevention & Remission Group, Cardiovascular & Metabolic Disease Research Unit from October 2013 to April 2014, and Lab head, Cardiovascular and Metabolic Disease Research Unit from May 2008 to September 2013. Bryan started their career at GSK as a Manager from 1999 to 2008.

Bryan Goodwin earned a Doctor of Philosophy (Ph.D.) degree in Cell/Cellular and Molecular Biology from the University of Sydney between 1996 and 1999.